CollPlant Biotechnologies (NASDAQ:CLGN) Receives Buy Rating from D. Boral Capital

CollPlant Biotechnologies (NASDAQ:CLGN)‘s stock had its “buy” rating reaffirmed by investment analysts at D. Boral Capital in a research note issued to investors on Tuesday,Benzinga reports. They currently have a $14.00 price target on the stock. D. Boral Capital’s target price would indicate a potential upside of 270.47% from the stock’s current price.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $11.00 price target on shares of CollPlant Biotechnologies in a report on Friday, November 29th.

CollPlant Biotechnologies Trading Up 1.6 %

Shares of NASDAQ:CLGN opened at $3.78 on Tuesday. CollPlant Biotechnologies has a 12-month low of $3.24 and a 12-month high of $6.75. The business has a 50 day moving average of $3.92 and a two-hundred day moving average of $4.34. The company has a market capitalization of $43.27 million, a PE ratio of -2.45 and a beta of 0.86.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings results on Wednesday, November 27th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative return on equity of 77.05% and a negative net margin of 2,680.00%. During the same quarter in the previous year, the company earned ($0.38) EPS. Equities research analysts predict that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Hedge Funds Weigh In On CollPlant Biotechnologies

A hedge fund recently bought a new stake in CollPlant Biotechnologies stock. Benjamin Edwards Inc. purchased a new position in CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,810 shares of the company’s stock, valued at approximately $112,000. Benjamin Edwards Inc. owned approximately 0.21% of CollPlant Biotechnologies at the end of the most recent quarter. 21.69% of the stock is owned by hedge funds and other institutional investors.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.